Digital Look

Welcome to Digital Look++,
you are not logged in

Allergy Therapeutics (AGY)

Pharma and Biotech

6.25p

2023-01-03 - Suspension of Listing

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
30-Jun-18	68.35	(6.90)	(1.27)p	n/a	n/a	n/a	n/a	0.0%
30-Jun-19	73.72	4.29	0.55p	25.5	n/a	n/a	n/a	0.0%
30-Jun-20	78.20	8.07	1.11p	12.6	0.1	+102%	n/a	0.0%
30-Jun-21	84.33	3.66	0.45p	55.6	n/a	-60%	n/a	0.0%
30-Jun-22	72.77	(12.66)	(2.14)p	n/a	n/a	n/a	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
30-Jun-23	70.34	(26.56)	(3.91)p	n/a	n/a	n/a	n/a	0.0%
30-Jun-24	82.10	(17.46)	(2.56)p	n/a	n/a	n/a	n/a	0.0%
30-Jun-25	106.00	(26.80)	(2.00)p	n/a	n/a	n/a	n/a	0.0%

Half-Year Trading Update 2023	20-Jan-2023	07:00	RNS
NOTICE OF 2022 ANNUAL GENERAL MEETING	13-Jan-2023	17:27	RNS
Suspension - Allergy Therapeutics plc	03-Jan-2023	07:30	RNS

Allergy Therapeutics confident in funding as res...	20-Jan-2023	ShareCast
Allergy Therapeutics pauses production at Freema...	04-Oct-2022	ShareCast
Allegy Therapeutics trades 'robustly' in tough y...	15-Jul-2022	ShareCast

Allergy drug firm hit by trials setback	12-Jul-2007	The Independent
Need to Know: Global Business Briefing	25-Mar-2006	Times

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.